Literature DB >> 10786260

Community pharmacist outreach program directed at physicians treating congestive heart failure.

C J Turner1, P Parfrey, K Ryan, R Miller, A Brown.   

Abstract

The predictive value of digoxin and furosemide treatment for identifying patients receiving treatment for congestive heart failure (CHF), the use of angiotensin-converting-enzyme (ACE) inhibitors in this population, and the ability of a pharmacist outreach program to address underutilization of ACE inhibitors were studied. All physicians and owner-managers of community pharmacies on Newfoundland's Avalon Peninsula were asked to participate in the study. Pharmacists who agreed to participate were asked to list patients of the participating physicians with prescriptions for (1) furosemide and digoxin with and without an ACE inhibitor or angiotensin II-receptor inhibitor and (2) an ACE inhibitor. Physicians were visited by a pharmacist and asked whether each of their patients receiving digoxin and furosemide was being treated for CHF and to identify further cases of CHF among their patients receiving an ACE inhibitor. Intervention-group physicians received academic detailing on the use and dosage of ACE inhibitors and angiotensin II-receptor inhibitors for CHF. Both groups were reinterviewed after three months to establish what if any changes in therapy had occurred for each patient discussed during the first visit. The positive predictive value of digoxin and furosemide treatment for identifying patients receiving treatment for CHF was 94%. Seventy-six percent of patients identified by physicians as CHF patients who were taking digoxin and furosemide were treated with an ACE inhibitor. Thirty-six percent of patients treated with an ACE inhibitor for CHF received the targeted dosage. Four physicians stated that the outreach visit influenced their prescribing, but there was no significant difference in ACE inhibitor prescribing between the intervention and control groups. A pharmacist outreach program involving the use of prescription records and academic detailing did not affect prescribing or dosages of ACE inhibitors but demonstrated value as a quality assurance tool.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786260     DOI: 10.1093/ajhp/57.8.747

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  A qualitative study of the contribution of pharmacists to heart failure management in Scotland.

Authors:  Alexander M Clark; John J V McMurray; Caroline E Morrison; David L Murdoch; Simon Capewell; Margaret E Reid
Journal:  Pharm World Sci       Date:  2005-12

Review 2.  Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns.

Authors:  Nancy Nkansah; Olga Mostovetsky; Christine Yu; Tami Chheng; Johnny Beney; Christine M Bond; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

Review 3.  The Impact of Pharmacist-Based Services Across the Spectrum of Outpatient Heart Failure Therapy.

Authors:  Lucianne M West; J Bradley Williams; Kathleen D Faulkenberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.